Measures of success
An infographic snapshot of UT Health San Antonio’s Joe R. and Teresa Lozano Long School of Medicine
2022 Research Funding
$144.4 MILLION Total Organized Research Funding
$120.1 MILLION National Institutes of Health
$8.3 MILLION U.S. Department of Defense
$185.3 MILLION All Federal Funding
$190.3 MILLION Total Sponsored Programs Funding
Top 40 Departmental Blue Ridge Rankings
23 Pharmacology
25 Cellular & Integrative Physiology
25 Molecular Medicine
26 Cell Systems & Anatomy
29 Urology
30 Population Health Sciences
31 Neurology
36 Obstetrics & Gynecology
Centers and Institutes
The University of Texas Health Science Center at San Antonio is the only university in the United States with an NCI-designated Cancer Center, an NIA-funded Nathan Shock Center, an NIA-funded Claude Pepper Center, an NIA-designated Alzheimer’s Disease Research Center, and an NCATS-funded Clinical and Translational Science Institute.
Mays Cancer Center at UT Health San Antonio
South Texas’ only National Cancer Institute-Designated Cancer Center.
Sam and Ann Barshop Institute for Longevity and Aging Studies
The only aging center in the nation that holds two National Institute on Aging-funded care centers:
1. San Antonio Claude D. Pepper Older Americans Independence Center (1 of 14 in U.S.).
2. San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging (1 of 6 in U.S.).
Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases
The Biggs Institute is leading Texas’ only NIH-funded Alzheimer’s Disease Research Center. The institute provides a comprehensive network of clinical care with access to the most advanced treatment through clinical trials.
Institute for Integration of Medicine and Science
IIMS houses an NIH-funded Clinical and Translational Science Award and integrates laboratory and clinical research for UT Health San Antonio and its partners.
South Texas Research Organizational Network Guiding Studies on Trauma and Resilience
STRONG STAR is a multidisciplinary and multi-institutional research consortium funded by the Department of Defense and Veterans Administration to develop and evaluate the most effective early interventions possible for posttraumatic stress disorder.
Clinical Trials From Our Own Science
NCT04230499
Phase 2A Trial of Encapsulated Rapamycin (eRapa)to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
NCT04886622
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, inPatients With Relapsed/Refractory Malignancies
NCT03776071
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added toTemozolomide During and Following RadiationTherapy in Newly Diagnosed Glioblastoma PatientsWho Possess the Novel Genomic Biomarker DGM1
NCT04608448
An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)
NCT04559230
A Phase 2, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
NCT02342379
TH-302 in Combination with Bevacizumab for Glioblastoma
NCT03091660
S1602: Different Strains of BCG with or without Vaccine in High Grade Non-Muscle Invasive Bladder Cancer
NCT019063852
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
NCT Pending
Phase 2 Trial with a Safety Run-in Evaluation of GC4711, a MnSOD Mimetic, Combined with a CDK4/6 Inhibitor(Palb) and an Estrogen Therapy (ET) Agent (Fulv) in Women with ET-Resistance/Recurrent/Metastatic Disease
NCT Pending
A Subject-Blinded First-in-human Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of AST-004 as a Short Intravenous Infusion in Healthy Adult Subjects
